Unconjugated hyperbilirubinemia, which did not subside even after 3 weeks of birth, was observed in a neonate. On investigating, liver enzymes, PT/INR and albumin levels were normal. No hemolysis was seen on a peripheral blood smear. A drop in bilirubin level was observed within a week after treatment with phenobarbital. What is the most likely diagnosis?

Correct Answer: D. Crigler Najjar type 2

Crigler-Najjar type 2 (CN-II) is characterized by unconjugated hyperbilirubinemia due to partial deficiency of UDP-glucuronosyltransferase (UGT1A1) enzyme. The clinical presentation here is pathognomonic: persistent unconjugated hyperbilirubinemia beyond 3 weeks of life in a neonate with normal liver synthetic function (normal PT/INR, albumin), no hemolysis, and dramatic response to phenobarbital within a week. Phenobarbital induces UGT1A1 enzyme expression, which is the hallmark therapeutic response in CN-II. Unlike CN-I (which has complete enzyme deficiency and does not respond to phenobarbital), CN-II retains residual enzyme activity (~10% of normal) that can be upregulated by enzyme inducers. The normal liver enzymes and albumin rule out hepatocellular injury or synthetic dysfunction. The absence of hemolysis excludes hemolytic causes. CN-II typically presents with bilirubin levels of 6–20 mg/dL and has an excellent prognosis with phenobarbital therapy, making it the most likely diagnosis in this clinical scenario.

Why the other options are wrong

A. Dubin Johnson syndrome — Dubin-Johnson is a conjugated hyperbilirubinemia disorder (cholestasis), not unconjugated. The question explicitly states unconjugated hyperbilirubinemia. Additionally, DJS presents with conjugated bilirubin >50% of total, and there is no response to phenobarbital. The dark urine and hepatomegaly typical of DJS are absent here. B. Rotor syndrome — Rotor syndrome, like Dubin-Johnson, causes conjugated hyperbilirubinemia with cholestasis, not unconjugated. It is a benign condition with bilirubin typically <4 mg/dL and does not respond to phenobarbital. The clinical presentation and enzyme response pattern do not match this diagnosis. C. Crigler Najjar type 1 — CN-I presents with severe unconjugated hyperbilirubinemia (>20 mg/dL) and does not respond to phenobarbital because there is complete absence of UGT1A1 enzyme activity. The dramatic drop in bilirubin within a week of phenobarbital therapy rules out CN-I. CN-I requires phototherapy and exchange transfusion; kernicterus is a major risk.

High-Yield Facts

Mnemonics

CN-I vs CN-II: Phenobarbital Response CN-I = No response (Complete enzyme deficiency, kernicterus risk). CN-II = Responds (Partial deficiency, residual enzyme can be induced). Use: When you see phenobarbital response in unconjugated hyperbilirubinemia → think CN-II. Unconjugated vs Conjugated Hyperbilirubinemia Syndromes Unconjugated: Gilbert, CN-I, CN-II (enzyme defects). Conjugated: Dubin-Johnson, Rotor (transport/excretion defects). Use: Dubin-Johnson and Rotor always present with dark urine and conjugated bilirubin >50%—opposite of this case.

NBE Trap

NBE pairs "phenobarbital response" with "benign unconjugated hyperbilirubinemia" to lure students into choosing Gilbert syndrome or missing the enzyme induction clue. The trap is that CN-I (severe, no response) and CN-II (moderate, responds) both cause unconjugated hyperbilirubinemia—the phenobarbital response is the discriminator, not the bilirubin level alone.</trap> <parameter name="textbookRef">Robbins & Cotran Ch. 18 (Liver and Biliary Tract); Harrison Ch. 297 (Jaundice and Hyperbilirubinemia); OP Ghai Pediatrics Ch. 8 (Neonatal Jaundice)

Clinical Pearl

In Indian neonatal units, unconjugated hyperbilirubinemia beyond 3 weeks warrants investigation for genetic causes. CN-II is often missed because it is less severe than CN-I and does not require exchange transfusion; however, a trial of phenobarbital (5 mg/kg/day) with bilirubin monitoring is diagnostic and therapeutic—a drop within 7 days confirms CN-II and avoids unnecessary investigations.